Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of FID-007 in Advanced Solid Tumors
NCT03537690Phase 1Active, not recruiting
- Sponsor
- University of Southern California
- Start
- May 2018
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fid-007 in solid tumor, sponsored by University of Southern California. Primary endpoints: Dose Limiting Toxicity at 28 days and Incidence of Adverse Events up to 2 years. Started May 2018; status: active, not recruiting.
02
Drugs
fid-007
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03537690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537690.